Lv7
5008 积分 2021-05-31 加入
Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy
1天前
待确认
Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia
6天前
已完结
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial
6天前
已关闭
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
7天前
已完结
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial
7天前
已关闭
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
8天前
已完结
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
14天前
已完结
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
17天前
已完结
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
19天前
已完结
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
19天前
已完结
皖公网安备34019202002308
